Hawaii vs New Jersey on USAspending: $4.1B vs $8.1B

Fifteen New Jersey awards for each Hawaii award

These figures are USAspending.gov obligations, not Treasury outlays. New Jersey’s $8.1B stock sits about $4.0 billion above Hawaii’s $4.1B. Place of performance in the award file is the scoring rule. New Jersey has more people (9,500,851 versus 1,446,146) and a vastly busier file. Hawaii still posts the higher per-capita reading.

New Jersey’s $8,084,032,234 is spread across 1,162,765 records. Hawaii’s $4,091,361,304 sits on 75,796. That is about 15 New Jersey awards for each Hawaii award. Dollars favor New Jersey; paperwork volume favors New Jersey as well. Intensity does not.

New Jersey’s 1,162,765 awards on $8,084,032,234 versus Hawaii’s 75,796 awards on $4,091,361,304 is a 15-to-1 paperwork gulf on stocks that are only about 2-to-1 apart. People of 9,500,851 versus 1,446,146 produce $92.49 versus $196.71. FY2026 of $878,702,039 versus $284,469,188 stays with New Jersey. Building construction versus pharmaceuticals is mix. A million-row file can still trail on intensity.

Hawaii’s $196.71 versus New Jersey’s $92.49

Hawaii’s 1,446,146 residents against $4.1B produce $196.71 per capita. New Jersey’s 9,500,851 residents against $8.1B produce $92.49. Intensity in Hawaii is more than double New Jersey’s even though New Jersey holds the larger stacked total, the million-row file, and the larger FY2026 window.

A $196.71 per-person reading is an intensity fact attached to $4.1B, not a household check. New Jersey’s $92.49 is attached to $8.1B. This table scores USAspending place of performance, not GDP. A 75,796-award file on $4.1B is consistent with a heavier typical booking than a 1,162,765-award file on $8.1B.

Buildings in Hawaii, pharmaceuticals in New Jersey

Hawaii’s top industry is commercial and institutional building construction. New Jersey’s is pharmaceutical preparation manufacturing. Those NAICS labels mark the largest grouping in each state’s file. Building awards and drug-manufacturing awards are different lead products sitting on $4.1B and $8.1B stocks.

A construction lead inside Hawaii’s 75,796-award file can include large facility actions without explaining every dollar. A pharmaceutical-preparation lead inside New Jersey’s 1,162,765-award file can sit among many smaller actions. Mix and scale both differ. Neither label is the entire stock.

FY2026: $284.5M in Hawaii vs $878.7M in New Jersey

FY2026 obligations are $284,469,188 in Hawaii and $878,702,039 in New Jersey. New Jersey remains ahead in the latest year, in the same direction as the stacked ranking. Recency questions belong in FY2026. The $4.1B and $8.1B totals remain the full USAspending.gov aggregate this comparison uses. Both years are obligations, not outlays.

Do not divide those FY figures by Hawaii’s 75,796 or New Jersey’s 1,162,765 all-years awards. Per capita of $196.71 on 1,446,146 residents versus $92.49 on 9,500,851 residents is the intensity comparison. FY2026 answers how the latest year booked. Stacked totals still favor New Jersey.

New Jersey’s $878,702,039 FY2026 versus Hawaii’s $284,469,188 stays with $8,084,032,234 versus $4,091,361,304. 1,162,765 awards versus 75,796 awards and 9,500,851 residents versus 1,446,146 residents produce $92.49 versus $196.71. Recency and scale favor New Jersey. Intensity favors Hawaii. Both years are USAspending.gov obligations, not outlays.

A row gulf with inverted intensity

New Jersey leads stacked dollars ($8.1B vs $4.1B), award count (1,162,765 vs 75,796), population (9,500,851 vs 1,446,146), and FY2026 ($878.7M vs $284.5M). Hawaii leads per capita ($196.71 vs $92.49). The distinctive fact is the 15-to-1 row gap on stocks that are only about 2-to-1 apart.

Commercial and institutional building construction versus pharmaceutical preparation manufacturing is mix inside files that contain many other industries. Use the Hawaii and New Jersey hubs for agencies and recipients. Keep both stocks labeled as USAspending.gov obligations.

A 15-to-1 row gap on a 2-to-1 dollar gap

New Jersey’s 1,162,765 awards on $8,084,032,234 versus Hawaii’s 75,796 awards on $4,091,361,304 is the paperwork gulf. Per capita of $92.49 on 9,500,851 residents versus $196.71 on 1,446,146 residents is the intensity inversion. FY2026 of $878,702,039 versus $284,469,188 stays with New Jersey. Those cuts should be read separately.

Commercial and institutional building construction versus pharmaceutical preparation manufacturing is mix. A million-row file and a 75,796-row file can sit on stocks that are only about 2-to-1 apart. Both figures are USAspending.gov obligations, not Treasury outlays. Place of performance is the scoring rule.

Questions

Which state has more federal spending, Hawaii or New Jersey?

New Jersey leads in stacked USAspending.gov obligations: $8,084,032,234 versus Hawaii’s $4,091,361,304. New Jersey has far more awards (1,162,765 vs 75,796) and more people (9,500,851 vs 1,446,146). Spending per capita is $196.71 in Hawaii and $92.49 in New Jersey. FY2026 obligations are $284.5M and $878.7M. These are obligations, not Treasury outlays.

Why does New Jersey have so many more awards than Hawaii?

New Jersey logs 1,162,765 awards on $8.1B. Hawaii logs 75,796 awards on $4.1B. New Jersey’s file is busier in rows on a larger stock, which implies a smaller typical booking. Per capita is $92.49 versus $196.71. Populations are 9,500,851 and 1,446,146. FY2026 favors New Jersey ($878.7M vs $284.5M).

What industries lead Hawaii and New Jersey federal awards?

Hawaii’s top industry is commercial and institutional building construction. New Jersey’s is pharmaceutical preparation manufacturing. Those slices sit on $4.1B and $8.1B obligation stocks. They mark the largest grouping in each file, not every award in either state. Award counts are 75,796 in Hawaii and 1,162,765 in New Jersey.

Are Hawaii vs New Jersey figures Treasury outlays?

No. SpendingVault uses USAspending.gov obligations. Outlays are cash payments and can lag. The $4.1B and $8.1B stacked totals and FY2026 amounts of $284.5M and $878.7M measure award commitments by place of performance, not Monthly Treasury Statement payments.